Overview

Postoperative aRCH With Cisplatin Versus aRCH With Cisplatin and Pembrolizumab in Locally Advanced Head and Neck Squamous Cell Carcinoma

Status:
Recruiting

Trial end date:
2024-08-01

Target enrollment:

Participant gender:

Summary

This trial evaluates the addition of pembrolizumab to standard postoperative adjuvant radiochemotherapy in the treatment of patients with locally advanced intermediate and high risk head and neck squamous cell carcinoma (HNSCC).

Phase:

Phase 2

Details

Lead Sponsor:

University of Leipzig

Treatments:

Cisplatin
Pembrolizumab